<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354340/" ref="ordinalpos=3193&amp;ncbi_uid=7293967&amp;link_uid=PMC4354340" image-link="/pmc/articles/PMC4354340/figure/fig8/" class="imagepopup">Figure 8.  From: Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer. </a></div><br /><div class="p4l_captionBody"><b>miR-4689 regulates EGFR signaling pathway.</b> A simplified scheme illustrating that exogenous miR-4689 can inhibit EGFR signaling through direct inhibition of both KRAS and AKT1. Endogenous miR-4689 expression is normally suppressed in mutated KRAS CRC.</div></div>